Alpelisib/iNOS Inhibitor/Nab-paclitaxel in Patients With HER2 Negative Metaplastic Breast Cancer (MpBC)
Alpelisib/iNOS Inhibitor/Nab-paclitaxel in Patients With HER2 Negative Metaplastic Breast Cancer (MpBC)
Recruiting · NCT05660083 · Registry updated 2026-06-04Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Alpelisib/iNOS Inhibitor/Nab-paclitaxel in Patients With HER2 Negative Metaplastic Breast Cancer (MpBC) | Neoplasms by Site, Skin and Connective Tissue Diseases, breast disorder, breast neoplasm, metaplastic breast carcinoma, neoplasm, skin disorder, triple-negative breast carcinoma | Recruiting | Phase 2 | 2026-06-04 | NCT05660083 |
2 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| Novartis Pharmaceuticals | 432 |
| The Methodist Hospital Research Institute | 124 |
3 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| Houston Methodist Neal Cancer Center | Houston | United States | 10 |
| National Institute of Health Clinical Center | Bethesda | United States | 1 |
| The University of Texas MD Anderson Cancer Center | Houston | United States | 207 |